Business Context and Reporting Period
This Form 8-K is a current report filed by Oramed Pharmaceuticals Inc. on March 30, 2022. The filing addresses a corporate governance event: the expansion of the Board of Directors and the appointment of a new director effective April 1, 2022.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is strictly limited to the disclosure of a director appointment.
Material Changes
The material change reported is the increase in the size of the Board of Directors by one seat. The Board appointed Mr. Yadin Rozov to fill the vacancy. No financial or operational changes are reported in this document.
Management Commentary and Governance Details
- New Director Profile: Mr. Rozov, age 44, brings over 20 years of experience in capital markets, corporate finance, and investment banking. He is the founder and managing partner of Terrace Edge Ventures LLC (since January 2022).
- Prior Experience: Previously served as a Partner at GoldenTree Asset Management LLC (2019-2021), CEO of Syncora Guarantee Inc. and Financial Guaranty UK Ltd, and as a Managing Director at Moelis & Company (2009-2019).
- Committee Assignments: The Board has not yet assigned Mr. Rozov to any specific committees.
- Compensation: Mr. Rozov will receive fees identical to those of other non-executive directors.
- Agreements: The Company expects to enter into a standard indemnification agreement with Mr. Rozov on terms consistent with existing agreements for directors and officers.
Key Facts for Investor Verification
- Verify the effective date of Mr. Rozov's appointment (April 1, 2022).
- Confirm the total number of directors on the Board following this expansion.
- Monitor future filings for Mr. Rozov's specific committee assignments.
- Note that this filing contains no financial performance data; refer to recent 10-Q or 10-K filings for financial metrics.